Diagnostic testing laboratory network P4 Diagnostix has acquired DNA confirmation testing provider Strand Diagnostics.
Strand offers DNA specimen provenance testing services, including its forensic know error system, along with its UroSeq germline testing offering. UroSeq can be used in accordance with guidelines from the U.S. National Comprehensive Cancer Network (NCCN) for patients with advanced prostate cancer, P4 Diagnostix said.
P4 said it intends to "reenergize" the brand and immediately resume testing, supplies, and logistics for all know error clients. The UroSeq assay will also immediately be offered to P4's customer base. In addition, the company noted that its clients will benefit from P4's partnership with cloud-based healthcare IT products and services firm VitalAxis.
Terms of the deal were not disclosed.
